Literature DB >> 20920943

Chemotherapy in anterior instrumentation for spinal tuberculosis: highlighting a 9-month three-drug regimen.

Li-Yang Dai1, Lei-Sheng Jiang, Yu-Ren Wang, Sheng-Dan Jiang.   

Abstract

BACKGROUND: Anterior instrumentation has been used for surgical treatment of spinal tuberculosis, but there are different regimens of antituberculous chemotherapy used in combination with surgical intervention. The objective of this prospective study was to determine the efficacy of an antituberculous chemotherapy regimen by following a series of patients with spinal tuberculosis, for a minimum of 3 years, who underwent single-stage anterior radical debridement, autogenous bone grafting, and instrumentation.
METHODS: The clinical and radiographic outcomes of these patients were analyzed with special reference to postoperative chemotherapy with a 9-month three-drug regimen. A total of 57 consecutive patients were treated surgically with single-stage anterior radical debridement, autogenous bone grafting, and instrumentation between 1999 and 2004. These patients received postoperative antituberculous chemotherapy with a 9-month three-drug regimen of isoniazid, rifampicin, and ethambutol. They were followed for 3-8 years (average = 5.5 years) with clinical and radiologic outcomes examined at each follow-up visit.
RESULTS: All patients received postoperative chemotherapy for 9 months except two for whom postoperative chemotherapy was discontinued 4 and 6 months after surgery because of noncompliance. All patients experienced complete or significant relief of cervical or back pain, rapid improvement of neurologic function, and kyphotic correction. Bony fusion and eradication of the infection were achieved in all patients, with no recurrence of the tuberculosis.
CONCLUSIONS: In conclusion, postoperative chemotherapy with the 9-month three-drug regimen of isoniazid, rifampicin, and ethambutol is effective when combined with surgical treatment of spinal tuberculosis using single-stage anterior autogenous bone grafting and instrumentation.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20920943     DOI: 10.1016/j.wneu.2010.02.023

Source DB:  PubMed          Journal:  World Neurosurg        ISSN: 1878-8750            Impact factor:   2.104


  6 in total

1.  Is duration of preoperative anti-tuberculosis treatment a risk factor for postoperative relapse or non-healing of spinal tuberculosis?

Authors:  Hai-Long Ren; Jian-Ming Jiang; Ji-Xing Wang; Dong-Bin Qu; Jian-Ting Chen
Journal:  Eur Spine J       Date:  2016-03-07       Impact factor: 3.134

2.  One-stage surgical treatment for thoracic and lumbar Spinal tuberculosis by transpedicular fixation, debridement, and combined interbody and posterior fusion via a posterior-only approach.

Authors:  Bing Ran; Yuan-Long Xie; Lei Yan; Lin Cai
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2016-07-28

3.  Surgical treatment of selected patients with multilevel contiguous thoracolumbar spinal tuberculosis by only posterior instrumentation without any bone fusion.

Authors:  Xiongjie Shen; Xiangwang Huang; Sheng Xiao; Hongzhe Liu; Yi Zhang; Tiecheng Xiang; Guoping Wang; Bin Sheng; Shu Huang; Xiangyang Liu
Journal:  Int J Clin Exp Med       Date:  2015-10-15

4.  One-stage posterior-only approach in surgical treatment of single-segment thoracic spinal tuberculosis with neurological deficits in adults: a retrospective study of 34 cases.

Authors:  Hao Zeng; Penghui Zhang; Xiongjie Shen; Chengke Luo; Zhengquan Xu; Yupeng Zhang; Zheng Liu; Xiyang Wang
Journal:  BMC Musculoskelet Disord       Date:  2015-08-05       Impact factor: 2.362

5.  Analysis and therapeutic schedule of the postoperative recurrence of bone tuberculosis.

Authors:  Lei Yang; Zhonghe Liu
Journal:  J Orthop Surg Res       Date:  2013-12-17       Impact factor: 2.359

6.  Anterior versus posterior surgical approach for lumbosacral tuberculosis.

Authors:  Bolong Zheng; Dingjun Hao; Hua Guo; Baorong He
Journal:  J Int Med Res       Date:  2018-03-27       Impact factor: 1.671

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.